D2 receptor

Target id: 215

Nomenclature: D2 receptor

Family: Dopamine receptors

Annotation status:  image of a green circle Annotated and expert reviewed. Please contact us if you can help with updates.  » Email us

Gene and Protein Information
class A G protein-coupled receptor
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 7 443 11q23 DRD2 dopamine receptor D2 8,38
Mouse 7 444 9 A5.3 Drd2 dopamine receptor D2 69
Rat 7 444 8q24 Drd2 dopamine receptor D2 8,21
Gene and Protein Information Comments
The human D2 receptor exists as two alternatively spliced isoforms [37]. The 443 amino acid receptor is the long form (D2L). The short form (D2S) is 414 amino acids long.
Previous and Unofficial Names
D2A and D2B
dopamine D2 receptor
dopamine receptor 2
D2 receptor
D2R
D2(415) and D2(444)
Database Links
ChEMBL Target
DrugBank Target
Ensembl Gene
Entrez Gene
GPCRDB
GeneCards
GenitoUrinary Development Molecular Anatomy Project
HomoloGene
Human Protein Reference Database
InterPro
KEGG Gene
OMIM
Orphanet Gene
PharmGKB Gene
PhosphoSitePlus
Protein Ontology (PRO)
RefSeq Nucleotide
RefSeq Protein
TreeFam
UniGene Hs.
UniProtKB
Wikipedia
Natural/Endogenous Ligands
dopamine
Agonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
rotigotine Hs Agonist 10.22 pKi 34
pKi 10.22 (Ki 6x10-11 M) [34]
aripiprazole Rn Partial agonist 9.7 pKi 84
pKi 9.7 [84]
brexpiprazole Hs Partial agonist 9.52 pKi 59
pKi 9.52 (Ki 3x10-10 M) [59]
lisuride Hs Partial agonist 9.2 – 9.5 pKi 67
pKi 9.2 – 9.5 [67]
terguride Hs Partial agonist 9.1 pKi 67
pKi 9.1 [67]
cabergoline Hs Partial agonist 9.0 – 9.2 pKi 67
pKi 9.0 – 9.2 [67]
aripiprazole Hs Partial agonist 9.1 pKi 108
pKi 9.1 (Ki 8x10-10 M) [108]
roxindole Hs Partial agonist 8.6 pKi 67
pKi 8.6 [67]
cariprazine Hs Partial agonist 8.24 pKi 1
pKi 8.24 (Ki 5.7x10-9 M) [1]
Description: Binding affinity to human dopamine D2L receptor
(-)-N-porphynorapomorphine Hs Full agonist 7.5 – 8.9 pKi 36,82
pKi 7.5 – 8.9 [36,82]
ropinirole Hs Agonist 8.14 pKi 41
pKi 8.14 (Ki 7.2x10-9 M) [41]
sumanirole Hs Full agonist 8.1 pKi 65
pKi 8.1 (Ki 9x10-9 M) [65]
bromocriptine Hs Full agonist 7.3 – 8.3 pKi 36,67,82
pKi 7.3 – 8.3 [36,67,82]
apomorphine Rn Partial agonist 7.6 pKi 97
pKi 7.6 [97]
pergolide Hs Full agonist 7.5 – 7.6 pKi 67
pKi 7.5 – 7.6 [67]
bromocriptine Rn Partial agonist 7.3 pKi 97
pKi 7.3 [97]
piribedil Hs Partial agonist 6.8 – 6.9 pKi 67
pKi 6.8 – 6.9 [67]
7-OH-DPAT Hs Full agonist 5.6 – 7.6 pKi 22,36,58
pKi 5.6 – 7.6 [22,36,58]
apomorphine Hs Partial agonist 5.7 – 7.5 pKi 22,36,67,82,95
pKi 5.7 – 7.5 [22,36,67,82,95]
quinpirole Hs Full agonist 4.9 – 7.7 pKi 22,66,73,95,97,103
pKi 4.9 – 7.7 [22,66,73,95,97,103]
pramipexole Hs Full agonist 5.1 – 7.4 pKi 66,82
pKi 5.1 – 7.4 [66,82]
7-OH-DPAT Rn Full agonist 6.2 pKi 30
pKi 6.2 [30]
dopamine Hs Full agonist 4.7 – 7.2 pKi 22,36,82
pKi 4.7 – 7.2 [22,36,82]
PD 128907 Hs Full agonist 5.4 – 6.4 pKi 75,82
pKi 5.4 – 6.4 [75,82]
dopamine Rn Full agonist 5.3 – 6.4 pKi 84,97
pKi 5.3 – 6.4 [84,97]
7-trans-OH-PIPAT Hs Full agonist 5.6 pKi 30
pKi 5.6 [30]
quinelorane Hs Full agonist 5.5 – 5.7 pKi 68,95
pKi 5.5 – 5.7 [68,95]
benzquinamide Hs Agonist 5.4 pKi 39
pKi 5.4 (Ki 3.964x10-6 M) [39]
quinpirole Rn Full agonist 5.2 pKi 97
pKi 5.2 [97]
aripiprazole Hs Partial agonist 7.42 pEC50 3
pEC50 7.42 (EC50 3.8x10-8 M) [3]
Description: Measuring cAMP production via the Gi-coupled signaling pathway
vilazodone Hs Agonist 6.18 pIC50 42
pIC50 6.18 (IC50 6.66x10-7 M) [42]
View species-specific agonist tables
Agonist Comments
Tergoride is a partial agonist at the D2S receptor and an antagonist at the D2L receptor.
Roxindole is a partial agonist at the D2S receptor and an antagonist at the D2L receptor.
Although benzquinamide has higher affinity for α-adrenoceptors, it is suggested in [39] that it is more likely that drug-induced modulation of D2 receptor activity is responsible for the drug's antiemetic action.
Antagonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
[3H]nemonapride Hs Antagonist 10.9 pKd 60
pKd 10.9 [60]
[3H]spiperone Rn Antagonist 10.2 pKd 21,43,109
pKd 10.2 (Kd 5.7x10-11 M) [21,43,109]
[3H]raclopride Rn Antagonist 8.9 pKd 53
pKd 8.9 (Kd 1.2x10-9 M) [53]
[3H]N-methylspiperone Rn Antagonist 10.7 pKi 84
pKi 10.7 [84]
blonanserin Hs Antagonist 9.85 pKi 71
pKi 9.85 (Ki 1.4x10-10 M) [71]
pipotiazine Hs Antagonist 9.7 pKi 96
pKi 9.7 (Ki 2x10-10 M) [96]
risperidone Hs Antagonist 9.36 pKi 10
pKi 9.36 (Ki 4.4x10-10 M) [10]
perospirone Hs Antagonist 9.22 pKi 89
pKi 9.22 (Ki 6x10-10 M) [89]
perphenazine Hs Antagonist 8.85 – 9.59 pKi 50,88
pKi 8.85 – 9.59 (Ki 1.4x10-9 – 2.6x10-10 M) [50,88]
eticlopride Hs Antagonist 9.2 pKi 58,100
pKi 9.2 [58,100]
trifluoperazine Hs Antagonist 8.89 – 9.02 pKi 50,90
pKi 8.89 – 9.02 (Ki 1.3x10-9 – 9.6x10-10 M) [50,90]
asenapine Hs Antagonist 8.92 pKi 93
pKi 8.92 (Ki 1.2x10-9 M) [93]
spiperone Rn Antagonist 8.4 – 9.4 pKi 58,68,97,100
pKi 8.4 – 9.4 [58,68,97,100]
terguride Hs Antagonist 8.9 pKi 67
pKi 8.9 [67]
fluphenazine Hs Antagonist 8.84 pKi 81
pKi 8.84 (Ki 1.44x10-9 M) [81]
flupentixol Hs Antagonist 8.82 pKi 36
pKi 8.82 (Ki 1.5x10-9 M) [36]
nafadotride Rn Antagonist 8.8 pKi 84
pKi 8.8 [84]
lurasidone Rn Antagonist 8.77 pKi 44
pKi 8.77 (Ki 1.68x10-9 M) [44]
olanzapine Hs Antagonist 8.68 pKi 10
pKi 8.68 (Ki 2.1x10-9 M) [10]
mesoridazine Hs Antagonist 8.66 pKi 29
pKi 8.66 (Ki 2.2x10-9 M) [29]
roxindole Hs Antagonist 8.6 pKi 67
pKi 8.6 [67]
ziprasidone Hs Antagonist 8.55 pKi 10
pKi 8.55 (Ki 2.8x10-9 M) [10]
raclopride Rn Antagonist 7.7 – 9.3 pKi 84,97
pKi 7.7 – 9.3 [84,97]
nafadotride Hs Antagonist 8.5 pKi 83
pKi 8.5 [83]
domperidone Rn Antagonist 8.5 pKi 97
pKi 8.5 [97]
sertindole Hs Antagonist 8.04 – 8.92 pKi 49-50,88
pKi 8.04 – 8.92 (Ki 9.1x10-9 – 1.2x10-9 M) [49-50,88]
prochlorperazine Hs Antagonist 8.44 pKi 12
pKi 8.44 (Ki 3.61x10-9 M) [12]
haloperidol Rn Antagonist 8.3 pKi 97
pKi 8.3 [97]
(+)-sulpiride Hs Antagonist 8.22 pKi 36
pKi 8.22 (Ki 6x10-9 M) [36]
L-741,626 Hs Antagonist 7.9 – 8.5 pKi 40,52
pKi 7.9 – 8.5 [40,52]
domperidone Hs Antagonist 7.9 – 8.4 pKi 36,95
pKi 7.9 – 8.4 [36,95]
loxapine Hs Antagonist 7.92 – 8.3 pKi 50,90
pKi 7.92 – 8.3 (Ki 1.2x10-8 – 5x10-9 M) [50,90]
haloperidol Hs Antagonist 7.4 – 8.8 pKi 36,58,66,95,101
pKi 7.4 – 8.8 [36,58,66,95,101]
(+)-butaclamol Hs Antagonist 7.5 – 8.7 pKi 22,36,58,100
pKi 7.5 – 8.7 [22,36,58,100]
raclopride Hs Antagonist 8.0 pKi 68
pKi 8.0 [68]
zotepine Hs Antagonist 7.96 pKi 87
pKi 7.96 (Ki 1.1x10-8 M) [87]
pimozide Hs Antagonist 7.0 – 8.8 pKi 36,95
pKi 7.0 – 8.8 [36,95]
amisulpride Hs Antagonist 7.8 – 8.0 pKi 61,95,97
pKi 7.9 – 8.0 [61,95]
pKi 7.8 [97]
pimozide Rn Antagonist 7.6 pKi 97
pKi 7.6 [97]
sulpiride Hs Antagonist 7.22 – 7.92 pKi 22
pKi 7.22 – 7.92 (Ki 6x10-8 – 1.2x10-8 M) [22]
metoclopramide Mm Antagonist 7.54 pKi 63
pKi 7.54 (Ki 2.88x10-8 M) [63]
chlorpromazine Rn Antagonist 7.5 pKi 97
pKi 7.5 [97]
chlorpromazine Hs Antagonist 7.0 – 7.6 pKi 36,95
pKi 7.0 – 7.6 [36,95]
quetiapine Hs Antagonist 7.2 pKi 10
pKi 7.2 (Ki 6.9x10-8 M) [10]
(-)-sulpiride Hs Antagonist 6.28 – 8.0 pKi 36,95,100
pKi 6.28 – 8.0 (Ki 5.2x10-7 – 1x10-8 M) [36,95,100]
(+)-sulpiride Rn Antagonist 7.0 pKi 97
pKi 7.0 [97]
trans-flupenthixol Hs Antagonist 6.92 pKi 36
pKi 6.92 (Ki 1.2x10-7 M) [36]
(+)-UH232 Hs Antagonist 6.4 – 7.1 pKi 36,97
pKi 6.4 – 7.1 [36,97]
promazine Hs Antagonist 6.52 pKi 23
pKi 6.52 (Ki 3x10-7 M) [23]
(+)-UH232 Rn Antagonist 6.4 pKi 97
pKi 6.4 [97]
clozapine Hs Antagonist 5.8 – 6.9 pKi 36,58,93,95,100
pKi 5.8 – 6.9 [36,58,93,95,100]
clozapine Rn Antagonist 6.2 pKi 97
pKi 6.2 [97]
(+)-S-14297 Hs Antagonist 5.5 pKi 68
pKi 5.5 [68]
(+)-SCH-23390 Hs Antagonist 5.3 pKi 36
pKi 5.3 [36]
UNC9975 Hs Antagonist 8.96 pEC50 3
pEC50 8.96 (EC50 1.1x10-9 M) [3]
Description: Antagonism of D2-mediated β-arrestin-2 translocation measured using the Tango assay
UNC0006 Hs Antagonist 8.92 pEC50 3
pEC50 8.92 (EC50 1.2x10-9 M) [3]
Description: Antagonism of D2-mediated β-arrestin-2 translocation measured using the Tango assay
UNC9994 Hs Antagonist 8.21 pEC50 3
pEC50 8.21 (EC50 6.1x10-9 M) [3]
Description: Antagonism of D2-mediated β-arrestin-2 translocation measured using the Tango assay
iloperidone Rn Antagonist 6.96 pIC50 98
pIC50 6.96 (IC50 1.1x10-7 M) [98]
Description: Measuring displacement of [3H]spiperone from rat striatum.
View species-specific antagonist tables
Antagonist Comments
Tergoride and roxindole act as a partial agonists at the D2S receptor and as antagonists at the D2L receptor.
Perphenazine is an antagonist at both the D2S and D2L receptors [99].
The approved drug mesoridazine, although consisting of 4 stereoisomers, appears to be selective for the D2 receptor [29], especially when examining the data for the two highest affinity isomers, compounds 2 and 5. Across the 3 dopamine receptors, compounds 2 and 5 have the same order of potency (D2>D3>D1). The data shown in the table above is for compound 2. Mesoridazine is also a selective antagonist of the serotonin 5-HT2A receptor.
Zotepine has a Ki of 5.4nM for the D2S receptor isoform [87].
The β-arrestin biased ligands UNC9975, UNC0006 and UNC9994, do not activate D2 receptor-mediated Gi-regulated inhibition of cAMP production, but rather are functionally-selective antagonists of the interaction between D2 receptor and β-arrestin-2 [3].
Allosteric Modulators
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
​SB269652 Hs Negative 6.38 pKB 56
pKB 6.38 (KB 4.16x10-7 M) [56]
Description: Allosteric reduction of dopamine binding in a radioligand binding assay
Primary Transduction Mechanisms
Transducer Effector/Response
Gi/Go family Adenylate cyclase inhibition
References:  45,70,72
Secondary Transduction Mechanisms
Transducer Effector/Response
Potassium channel
References:  28
Tissue Distribution
Adrenal cortex.
Species:  Human
Technique:  Autoradiography.
References:  4
Cerebral, mesenteric and renal arteries.
Species:  Rat
Technique:  Autoradiography.
References:  5
Striatonigral neurons.
Species:  Rat
Technique:  Immunofluorescence.
References:  9
Striatum.
Species:  Rat
Technique:  in situ hybridization.
References:  24
Expression Datasets

Show »

Log average relative transcript abundance in mouse tissues measured by qPCR from Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical profiling of G protein-coupled receptor expression. Cell, 135(3): 561-71. [PMID:18984166] [Raw data: website]

There should be a chart of expression data here, you may need to enable JavaScript!
Functional Assays
Measurement of Cl- currents in Xenopus oocytes transfected with murine D2L and D2S receptors.
Species:  Mouse
Tissue:  Xenopus oocytes.
Response measured:  Stimulation of Cl- influx.
References:  94
Measurement of inwardly rectifying K+ currents in Xenopus oocytes transfected with the human D2 receptor.
Species:  Human
Tissue:  Xenopus oocytes.
Response measured:  Activation of GIRK1 channels.
References:  74
Measurement of cAMP levels in GH4C1 cells transfected with the D2 receptor.
Species:  Rat
Tissue:  GH4C1 cells.
Response measured:  Inhibition of cAMP accumulation.
References:  2
Measurement of prolactin secretion in GH4C1 cells transfected with the D2 receptor.
Species:  Rat
Tissue:  GH4C1 cells.
Response measured:  Inhibition of prolactin secretion.
References:  2
Measurement of voltage-dependent potassium current in NG108-15 cells transfected witht the D2 receptor.
Species:  Rat
Tissue:  NG108-15 cells.
Response measured:  Inhibition of voltage-dependent potassium current.
References:  27
Measurement of activation of potassium channel in rat lactotrophs endogenously expressing the D2 receptor.
Species:  Rat
Tissue:  Lactotrophs.
Response measured:  Activation of potassium channel.
References:  28
Measurement of Ca2+ and cAMP levels in Ltk- cells transfected with both the long and short forms of the human D2 receptor.
Species:  Human
Tissue:  LTK- cells.
Response measured:  Stimulation of calcium mobilisation and cAMP accumulation.
References:  57
Measurement of [3H]thymidine incorporation in CHO cells transfected with the human D2 receptor.
Species:  Human
Tissue:  CHO cells.
Response measured:  [3H]thymidine incorporation.
References:  55
Measurement of cAMP levels in CHO cells transfected with the human D2 receptor.
Species:  Human
Tissue:  CHO cells.
Response measured:  Inhibition of cAMP accumulation.
References:  55
Measurement of [3H]arachidonic acid release from rat striatal neurons endogenously expressing the D2 receptors.
Species:  Rat
Tissue:  Striatal neurons.
Response measured:  Enhanced [3H]arachidonic acid release.
References:  85
Measurement of cAMP levels in HEK 293 cells transfected with the human D2 receptor.
Species:  Human
Tissue:  HEK 293 cells.
Response measured:  Inhibition of cAMP accumulation.
References:  64,106
Physiological Functions
Blockade enhances learning/memory.
Species:  Rat
Tissue:  In vivo.
References:  92
Stimulation of accumulation of cAMP in membrane particles of the rat kidney medulla.
Species:  Human
Tissue:  Membrane particles of the rat kidney medulla.
References:  6
Inhibits Na+-K+-adenosinetriphosphatase (ATPase) activity when a D1 agonist is co-administered with a D2 agonist.
Species:  Rat
Tissue:  Proximal tubule.
References:  15
Inhibition of (Na+)+K+)ATPase activity via synergism with the D1 receptor.
Species:  Rat
Tissue:  Isolated striatal neurons.
References:  16
Modulation of locomotor activity.
Species:  Rat
Tissue:  In vivo.
References:  19
Control of renal blood flow.
Species:  Human
Tissue:  In vivo.
References:  20
Modulation of striatal dopamine.
Species:  Rat
Tissue:  In vivo.
References:  48
Reward effects of morphine.
Species:  Rat
Tissue:  In vivo.
References:  62
Physiological Consequences of Altering Gene Expression
D2 receptor knockout mice are insensitive to the cataleptic effects of haloperidol.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  17
D2 receptor knockout mice are insensitive to the hypolocomotor and hypothermic effects of D2/D3 agonists.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  18
D2 receptor knockout mice exhibit d-amphetamine-induced disruption of prepulse inhibition, as seen in wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  76
D2 receptor knockout mice display Parkinsonian-like locomotor impairment when compared to the wild type.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  13,35
D2 receptor knockout mice exhibit hyperprolactinemia (controversy remains as to whether knockout mice display bradykinetic and/or cataleptic behaviour).
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  11,18,46-47,79-80,107
D2 receptor knockout mice exhibit abnormal synaptic plasticity.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  26
D2 receptor knockout mice do not exhibit autoreceptor-mediated inhibitory control of dopamine release in striatal synaptosomes, as seen in wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  54
D2 receptor knockout mice exhibit a decrease in dopamine transporter (DAT) activity.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  33
D2L receptor knockout mice (which still express the short form of the receptor, D2S) exhibit reduced levels of locomotion and rearing behaviour, as well as reduced haloperidol-induced catalepsy and inhibition of locomotor activity.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  105
D2 receptor knockout mice exhibit reduced ethanol-conditioned place preference.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  32
D2L receptor knockout mice exhibit reduced aggression.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  104
D2 receptor knockout mice do not exhibit autoinhibition of dopamine release.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  14,78
D2 receptor knockout mice exhibit increased rates of high-dose cocaine self-administration.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  25
D2 receptor knockout mice exhibit reduced locomotor activity and slower acquisition of a place-learning task.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  102
D2 receptor knockout mice exhibit altered dopamine release and uptake.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  86
D2 receptor knockout mice exhibit altered GABAergic neurotransmission.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  7
Phenotypes, Alleles and Disease Models Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
either: B6.129S2-Drd2 or (involves: 129S2/SvPas * C57BL/6)
MGI:94924  MP:0004163 abnormal adenohypophysis morphology PMID: 9247267 
Drd2tm1Yyw Drd2tm1Yyw/Drd2tm1Yyw
B6.129S4-Drd2
MGI:94924  MP:0009745 abnormal behavioral response to xenobiotic PMID: 11069937  12650980 
Drd2+|Drd2tm1Yyw Drd2tm1Yyw/Drd2+
B6.129S4-Drd2
MGI:94924  MP:0009745 abnormal behavioral response to xenobiotic PMID: 12650980 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2/J
MGI:94924  MP:0005535 abnormal body temperature PMID: 18486343 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2
MGI:94924  MP:0000913 abnormal brain development PMID: 11158626 
Drd2tm1Mok Drd2tm1Mok/Drd2tm1Mok
involves: 129S/SvEv * C57BL/6J * DBA/2J
MGI:94924  MP:0005418 abnormal circulating hormone level PMID: 9140068 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2
MGI:94924  MP:0002206 abnormal CNS synaptic transmission PMID: 11158626 
Drd1atm1Jcd|Drd2tm1Ebo Drd1atm1Jcd/Drd1atm1Jcd,Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6
MGI:94924  MGI:99578  MP:0003119 abnormal digestive system development PMID: 15272078 
Drd1atm1Jcd|Drd2tm1Ebo Drd1atm1Jcd/Drd1atm1Jcd,Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6
MGI:94924  MGI:99578  MP:0001663 abnormal digestive system physiology PMID: 15272078 
Drd2tm1Schm Drd2tm1Schm/Drd2tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MP:0001905 abnormal dopamine level PMID: 10391470 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MGI:94925  MP:0001905 abnormal dopamine level PMID: 10391470 
Drd2tm1Schm|Drd3+|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MGI:94925  MP:0001905 abnormal dopamine level PMID: 10391470 
Drd1atm1Jcd|Drd2+|Drd2tm1Ebo Drd1atm1Jcd/Drd1atm1Jcd,Drd2tm1Ebo/Drd2+
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6
MGI:94924  MGI:99578  MP:0003271 abnormal duodenum morphology PMID: 15272078 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0001927 abnormal estrous cycle PMID: 9247268 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0009016 abnormal estrus PMID: 9247268 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2
MGI:94924  MP:0002910 abnormal excitatory postsynaptic currents PMID: 11158626 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2/J
MGI:94924  MP:0003245 abnormal GABAergic neuron morphology PMID: 17409246 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0001406 abnormal gait PMID: 7566118 
Drd1atm1Jcd|Drd2tm1Ebo Drd1atm1Jcd/Drd1atm1Jcd,Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6
MGI:94924  MGI:99578  MP:0005645 abnormal hypothalamus physiology PMID: 15272078 
Drd1atm1Jcd|Drd2tm1Ebo Drd1atm1Jcd/Drd1atm1Jcd,Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6
MGI:94924  MGI:99578  MP:0008802 abnormal intestinal smooth muscle morphology PMID: 15272078 
Drd2tm1Schm Drd2tm1Schm/Drd2tm1Schm
B6.Cg-Drd2
MGI:94924  MP:0006001 abnormal intestinal transit time PMID: 16525059 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
B6.Cg-Drd2 Drd3
MGI:94924  MGI:94925  MP:0006001 abnormal intestinal transit time PMID: 16525059 
Drd1atm1Jcd|Drd2tm1Ebo Drd1atm1Jcd/Drd1atm1Jcd,Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6
MGI:94924  MGI:99578  MP:0000477 abnormal intestine morphology PMID: 15272078 
Drd2tm1Schm Drd2tm1Schm/Drd2tm1Schm
B6.Cg-Drd2
MGI:94924  MP:0006003 abnormal large intestinal transit time PMID: 16525059 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
B6.Cg-Drd2 Drd3
MGI:94924  MGI:94925  MP:0006003 abnormal large intestinal transit time PMID: 16525059 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2
MGI:94924  MP:0006299 abnormal latent inhibition of conditioning behavior PMID: 15061865 
Adora2atm1Jfc|Drd2tm1Low Adora2atm1Jfc/Adora2atm1Jfc,Drd2tm1Low/Drd2tm1Low
involves: 129 * C57BL/6
MGI:94924  MGI:99402  MP:0003313 abnormal locomotor activation PMID: 16280580 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
involves: 129 * C57BL/6
MGI:94924  MP:0003313 abnormal locomotor activation PMID: 16280580 
Drd2+|Drd2tm1(IL2RA)Koba Drd2tm1(IL2RA)Koba/Drd2+
B6.129P2-Drd2
MGI:94924  MP:0003313 abnormal locomotor activation PMID: 14534241 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
involves: 129S2/SvPas * C57BL/6J
MGI:94924  MP:0003313 abnormal locomotor activation PMID: 9547254 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2
MGI:94924  MP:0003313 abnormal locomotor activation PMID: 11566895  9547254 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
129S/Sv-Drd2
MGI:94924  MP:0003313 abnormal locomotor activation PMID: 9547254 
Drd2tm1Schm Drd2tm1Schm/Drd2tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MP:0001392 abnormal locomotor activity PMID: 10391470 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MGI:94925  MP:0001392 abnormal locomotor activity PMID: 10391470 
Drd2tm1Schm|Drd3+|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MGI:94925  MP:0001392 abnormal locomotor activity PMID: 10391470 
Drd2+|Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2+,Drd3tm1Schm/Drd3tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:94924  MGI:94925  MP:0001392 abnormal locomotor activity PMID: 10391470 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
involves: 129S2/SvPas * C57BL/6J
MGI:94924  MP:0001392 abnormal locomotor activity PMID: 9547254 
Drd2+|Drd2tm1Low Drd2tm1Low/Drd2+
involves: 129S2/SvPas * C57BL/6J
MGI:94924  MP:0001392 abnormal locomotor activity PMID: 9547254 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2
MGI:94924  MP:0001392 abnormal locomotor activity PMID: 10196569  9547254 
Drd2+|Drd2tm1Low Drd2tm1Low/Drd2+
B6.129S2-Drd2
MGI:94924  MP:0001392 abnormal locomotor activity PMID: 9547254 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
129S/Sv-Drd2
MGI:94924  MP:0001392 abnormal locomotor activity PMID: 9547254 
Drd2+|Drd2tm1Low Drd2tm1Low/Drd2+
129S/Sv-Drd2
MGI:94924  MP:0001392 abnormal locomotor activity PMID: 9547254 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0008324 abnormal melanotroph morphology PMID: 9717839 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2/J
MGI:94924  MP:0006009 abnormal neuronal migration PMID: 17409246 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0004811 abnormal neuron physiology PMID: 11069974 
Drd2tm1Schm Drd2tm1Schm/Drd2tm1Schm
B6.Cg-Drd2
MGI:94924  MP:0001666 abnormal nutrient absorption PMID: 16525059 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
B6.Cg-Drd2 Drd3
MGI:94924  MGI:94925  MP:0001666 abnormal nutrient absorption PMID: 16525059 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2
MGI:94924  MP:0002803 abnormal operant conditional behavior PMID: 15061865 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
either: B6.129S2-Drd2 or (involves: 129S2/SvPas * C57BL/6)
MGI:94924  MP:0000633 abnormal pituitary gland morphology PMID: 9247267 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0005646 abnormal pituitary gland physiology PMID: 9717839 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2
MGI:94924  MP:0003088 abnormal prepulse inhibition PMID: 10341260 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2
MGI:94924  MP:0003462 abnormal response to novel odor PMID: 16765459 
Drd2tm1Mok Drd2tm1Mok/Drd2tm1Mok
involves: 129S/SvEv * C57BL/6J * DBA/2J
MGI:94924  MP:0003463 abnormal single cell response PMID: 9140068 
Drd2tm1Mok Drd2tm1Mok/Drd2tm1Mok
involves: 129S/SvEv
MGI:94924  MP:0003463 abnormal single cell response PMID: 14684868 
Drd1atm1Jcd|Drd2+|Drd2tm1Ebo Drd1atm1Jcd/Drd1atm1Jcd,Drd2tm1Ebo/Drd2+
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6
MGI:94924  MGI:99578  MP:0000470 abnormal stomach morphology PMID: 15272078 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2
MGI:94924  MP:0000230 abnormal systemic arterial blood pressure PMID: 11566895 
Drd2+|Drd2tm1Low Drd2tm1Low/Drd2+
B6.129S2-Drd2
MGI:94924  MP:0000230 abnormal systemic arterial blood pressure PMID: 11566895 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2/J
MGI:94924  MP:0001529 abnormal vocalization PMID: 18382674 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0008294 abnormal zona fasciculata morphology PMID: 9717839 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0008295 abnormal zona reticularis morphology PMID: 9717839 
Drd1atm1Jcd|Drd2tm1Ebo Drd1atm1Jcd/Drd1atm1Jcd,Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6
MGI:94924  MGI:99578  MP:0009546 absent gastric milk in neonates PMID: 15272078 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2
MGI:94924  MP:0001899 absent long term depression PMID: 11158626 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0008299 adrenal cortical hyperplasia PMID: 9717839 
Drd2tm1Ebo Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * C57BL/6
MGI:94924  MP:0002690 akinesia PMID: 7566118 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2
MGI:94924  MP:0002570 alcohol aversion PMID: 10196569 
Drd1atm1Jcd|Drd2tm1Ebo Drd1atm1Jcd/Drd1atm1Jcd,Drd2tm1Ebo/Drd2tm1Ebo
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6
MGI:94924  MGI:99578  MP:0001438 aphagia PMID: 15272078 
Drd2tm1Low Drd2tm1Low/Drd2tm1Low
B6.129S2-Drd2
MGI:94924  MP:0001393 ataxia